Version May 2024
Fungal blepharitis or conjunctivitis: Ophthalmic: Instill 1 drop in conjunctival sac 4 to 6 times daily.
Fungal keratitis: Ophthalmic: Instill 1 drop in conjunctival sac every 1 to 2 hours, after 3 to 4 days reduce to one drop 6 to 8 times daily; usual course of therapy is 2 to 3 weeks or until resolution of active fungal keratitis (may be useful to gradually reduce dosage at 4- to 7-day intervals to assure elimination of organism).
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.
Refer to adult dosing.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Postmarketing:
Cardiovascular: Chest pain
Hypersensitivity: Hypersensitivity reaction
Nervous system: Paresthesia
Ophthalmic: Corneal opacity, eye discomfort, eye irritation, eye pain, foreign body sensation of eye, lacrimation, ocular hyperemia, periorbital edema, visual disturbance
Respiratory: Dyspnea
Hypersensitivity to natamycin or any component of the formulation
Disease-related concerns:
• Epithelial ulceration: Suspension may adhere to epithelial ulcers; retention of the suspension in the fornices occurs regularly.
Special populations:
• Contact lens wearers: Contains benzalkonium chloride, which may be absorbed by soft contact lenses; remove lenses prior to administration. Contact lenses should not be worn during treatment of ophthalmologic infections (including fungal blepharitis, conjunctivitis, and keratitis).
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only. Failure to improve (keratitis) after 7 to 10 days of administration suggests infection caused by a microorganism not susceptible to natamycin; efficacy as a single agent in fungal endophthalmitis has not been established.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Suspension, Ophthalmic:
Natacyn: 5% (15 mL [DSC])
Natacyn: 5% (15 mL) [contains benzalkonium chloride]
No
Suspension (Natacyn Ophthalmic)
5% (per mL): $37.89
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Ophthalmic: For topical ophthalmic use only. Shake well before using. Wash hands before and after use. Do not touch tip of applicator to eye or other surfaces.
Ocular fungal infections: Treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms, including Fusarium solani keratitis.
Natacyn may be confused with Naprosyn
None known.
There are no known significant interactions.
Animal reproduction studies have not been conducted.
It is not known if natamycin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering natamycin to nursing women.
Binds to sterol in fungal cell membrane and changes the cell wall permeability allowing for a reduction of cellular contents
Absorption: Ophthalmic: Systemic, not expected; Gastrointestinal: Poor
Distribution: Adheres to cornea, retained in conjunctival fornices; does not produce effective intraocular fluid concentrations
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
